Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial

2019348 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet Diabetes & Endocrinology

Volume 7, Issue 5, pp. 356-367

Field-Weighted Citation Impact: 25.66